CN113164523A - 呈现pd-l1的血小板逆转新发1型糖尿病 - Google Patents

呈现pd-l1的血小板逆转新发1型糖尿病 Download PDF

Info

Publication number
CN113164523A
CN113164523A CN201980080274.7A CN201980080274A CN113164523A CN 113164523 A CN113164523 A CN 113164523A CN 201980080274 A CN201980080274 A CN 201980080274A CN 113164523 A CN113164523 A CN 113164523A
Authority
CN
China
Prior art keywords
hours
days
disease
syndrome
platelets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980080274.7A
Other languages
English (en)
Chinese (zh)
Inventor
顾臻
王金强
张旭东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of CN113164523A publication Critical patent/CN113164523A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
CN201980080274.7A 2018-10-10 2019-10-10 呈现pd-l1的血小板逆转新发1型糖尿病 Pending CN113164523A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743857P 2018-10-10 2018-10-10
US62/743,857 2018-10-10
PCT/US2019/055524 WO2020077037A1 (en) 2018-10-10 2019-10-10 Pd-l1 presenting platelets reverse new-onset type 1 diabetes

Publications (1)

Publication Number Publication Date
CN113164523A true CN113164523A (zh) 2021-07-23

Family

ID=70165144

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980080274.7A Pending CN113164523A (zh) 2018-10-10 2019-10-10 呈现pd-l1的血小板逆转新发1型糖尿病

Country Status (6)

Country Link
US (1) US20210353679A1 (enExample)
EP (1) EP3863650A4 (enExample)
JP (1) JP2022512658A (enExample)
CN (1) CN113164523A (enExample)
CA (1) CA3115778A1 (enExample)
WO (1) WO2020077037A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694204A (zh) * 2021-08-26 2021-11-26 南方医科大学南方医院 一种治疗骨髓炎的组合物及其应用
CN116159149A (zh) * 2023-02-27 2023-05-26 上海中医药大学 一种基于血小板的免疫连接器的制备方法及应用
CN118599772A (zh) * 2024-06-12 2024-09-06 深圳市第三人民医院(深圳市肝病研究所) 工程化免疫细胞、包含其的药物组合物及制备方法和应用
CN119662531A (zh) * 2024-12-19 2025-03-21 中山大学·深圳 一种工程化血小板及其制备方法与其在1型糖尿病中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984219B (zh) * 2022-03-29 2023-06-27 浙江大学 Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055891A1 (en) * 2016-08-29 2018-03-01 Yong Zhao Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
WO2018053010A1 (en) * 2016-09-13 2018-03-22 North Carolina State University Platelet compositions and methods for the delivery of therapeutic agents
US20180214487A1 (en) * 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250682A4 (en) * 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180214487A1 (en) * 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
US20180055891A1 (en) * 2016-08-29 2018-03-01 Yong Zhao Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
WO2018053010A1 (en) * 2016-09-13 2018-03-22 North Carolina State University Platelet compositions and methods for the delivery of therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUWEI HE等: "Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis", NANO RESEARCH, vol. 11, no. 11, XP036635262, DOI: 10.1007/s12274-018-2126-5 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694204A (zh) * 2021-08-26 2021-11-26 南方医科大学南方医院 一种治疗骨髓炎的组合物及其应用
CN116159149A (zh) * 2023-02-27 2023-05-26 上海中医药大学 一种基于血小板的免疫连接器的制备方法及应用
CN118599772A (zh) * 2024-06-12 2024-09-06 深圳市第三人民医院(深圳市肝病研究所) 工程化免疫细胞、包含其的药物组合物及制备方法和应用
CN119662531A (zh) * 2024-12-19 2025-03-21 中山大学·深圳 一种工程化血小板及其制备方法与其在1型糖尿病中的应用

Also Published As

Publication number Publication date
WO2020077037A9 (en) 2020-06-11
EP3863650A1 (en) 2021-08-18
US20210353679A1 (en) 2021-11-18
JP2022512658A (ja) 2022-02-07
EP3863650A4 (en) 2022-09-14
WO2020077037A1 (en) 2020-04-16
CA3115778A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
US20210353679A1 (en) Pd-l1 presenting platelets reverse new-onset type 1 diabetes
Deng et al. Nanoparticles from cuttlefish ink inhibit tumor growth by synergizing immunotherapy and photothermal therapy
CN112543651B (zh) 使car t细胞恢复活力
Bryant et al. Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation
Makkouk et al. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer
RU2696876C2 (ru) Способы и композиции для устойчивой иммунотерапии
Gao et al. Tetrahedral framework nucleic acids induce immune tolerance and prevent the onset of type 1 diabetes
Lugani et al. Dual immunostimulatory pathway agonism through a synthetic nanocarrier triggers robust anti‐tumor immunity in murine glioblastoma
Wang et al. Boosting sono-immunotherapy of prostate carcinoma through amplifying domino-effect of mitochondrial oxidative stress using biodegradable cascade-targeting nanocomposites
KR20180129990A (ko) 골수종의 치료
CN112135639B (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
Yang et al. A new concept of enhancing immuno-chemotherapeutic effects against B16F10 tumor via systemic administration by taking advantages of the limitation of EPR effect
US20240245721A1 (en) Double sided chimeric antigen receptor (car) engineered cell membrane based drug delivery systems
CN114478772B (zh) 工程化免疫细胞、纳米凝胶及其制备方法和应用
Song et al. Applications of magnetite nanoparticles in cancer immunotherapies: present hallmarks and future perspectives
Chen et al. Boosting checkpoint immunotherapy with biomimetic nanodrug delivery systems
Wang et al. Polymersomal poly (I: C) self‐magnifies antitumor immunity by inducing immunogenic cell death and systemic immune activation
Zhang et al. Petaloid Metal–Organic Frameworks for Resiquimod Delivery To Potentiate Antitumor Immunity
EP2968504B1 (en) Compositions and methods for inducing apoptosis
Graham-Gurysh et al. Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice
Zhao et al. Nanomedicines Reshape the Tumor Microenvironment: Multidimensional Strategies from Modulating “Barriers” to Metabolic Intervention
WO2022115432A1 (en) Engineered cells functionalized with immune checkpoint molecules and uses thereof
Sun et al. Advancing immunomodulation in organ transplantation: the therapeutic potential of self-assembled rapamycin nanoparticles in allograft rejection
Huang et al. Copper-based nanoparticle co-loaded with natural PD-L1 inhibitor and 5-Fluorouracil for enhanced immunotherapy of hepatocellular carcinoma
EP3880178A1 (en) Novel nanoparticles of antiretroviral drugs, their preparation and their use for the treatment of viral infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723